JPWO2023102188A5 - - Google Patents

Info

Publication number
JPWO2023102188A5
JPWO2023102188A5 JP2024532799A JP2024532799A JPWO2023102188A5 JP WO2023102188 A5 JPWO2023102188 A5 JP WO2023102188A5 JP 2024532799 A JP2024532799 A JP 2024532799A JP 2024532799 A JP2024532799 A JP 2024532799A JP WO2023102188 A5 JPWO2023102188 A5 JP WO2023102188A5
Authority
JP
Japan
Prior art keywords
gapmer oligonucleotide
spacer
inventions
gapmer
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501682A5 (https=
JP2025501682A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/051663 external-priority patent/WO2023102188A1/en
Publication of JP2025501682A publication Critical patent/JP2025501682A/ja
Publication of JP2025501682A5 publication Critical patent/JP2025501682A5/ja
Publication of JPWO2023102188A5 publication Critical patent/JPWO2023102188A5/ja
Pending legal-status Critical Current

Links

JP2024532799A 2021-12-03 2022-12-02 改変された骨格化学を有するギャップマーアンチセンスオリゴヌクレオチド Pending JP2025501682A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163285888P 2021-12-03 2021-12-03
US202163285696P 2021-12-03 2021-12-03
US202163285705P 2021-12-03 2021-12-03
US202163285692P 2021-12-03 2021-12-03
US202163285665P 2021-12-03 2021-12-03
US63/285,665 2021-12-03
US63/285,692 2021-12-03
US63/285,696 2021-12-03
US63/285,705 2021-12-03
US63/285,888 2021-12-03
PCT/US2022/051663 WO2023102188A1 (en) 2021-12-03 2022-12-02 Gapmer antisense oligonucleotides with modified backbone chemistries

Publications (3)

Publication Number Publication Date
JP2025501682A JP2025501682A (ja) 2025-01-23
JP2025501682A5 JP2025501682A5 (https=) 2025-12-10
JPWO2023102188A5 true JPWO2023102188A5 (https=) 2025-12-10

Family

ID=86613042

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532799A Pending JP2025501682A (ja) 2021-12-03 2022-12-02 改変された骨格化学を有するギャップマーアンチセンスオリゴヌクレオチド

Country Status (5)

Country Link
EP (1) EP4441224A4 (https=)
JP (1) JP2025501682A (https=)
CN (1) CN119452086A (https=)
CA (1) CA3241316A1 (https=)
WO (1) WO2023102188A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024007790A (es) 2021-12-22 2024-09-06 Camp4 Therapeutics Corp Modulación de la transcripción génica utilizando oligonucleótidos antisentido dirigidos a arn reguladores.

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0673559A1 (en) 1992-12-14 1995-09-27 Honeywell Inc. Motor system with individually controlled redundant windings
WO1995006731A2 (en) * 1993-09-02 1995-03-09 Ribozyme Pharmaceuticals, Inc. Non-nucleotide containing enzymatic nucleic acid
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
AU9063398A (en) 1997-09-12 1999-04-05 Exiqon A/S Oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
EP1178999B1 (en) 1999-05-04 2007-03-14 Santaris Pharma A/S L-ribo-lna analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
US8604183B2 (en) 2002-11-05 2013-12-10 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
CA2504694C (en) 2002-11-05 2013-10-01 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
EP1661905B9 (en) 2003-08-28 2012-12-19 IMANISHI, Takeshi Novel artificial nucleic acids of n-o bond crosslinkage type
WO2005027962A1 (en) 2003-09-18 2005-03-31 Isis Pharmaceuticals, Inc. 4’-thionucleosides and oligomeric compounds
EP1869076A2 (en) * 2005-03-10 2007-12-26 Genentech, Inc. Methods and compositions for modulating vascular integrity
JP5342881B2 (ja) 2006-01-27 2013-11-13 アイシス ファーマシューティカルズ， インコーポレーテッド ６−修飾された二環式核酸類似体
EP2021008B1 (en) * 2006-04-07 2015-12-02 Idera Pharmaceuticals, Inc. Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8
EP2505649A1 (en) * 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of GCGR
AU2007249349B2 (en) 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
US20100190837A1 (en) 2007-02-15 2010-07-29 Isis Pharmaceuticals, Inc. 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
EP2152879B1 (en) * 2007-05-01 2012-11-14 Santaris Pharma A/S Rna antagonist compounds for the modulation of beta-catenin
EP2170917B1 (en) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
CA2692579C (en) 2007-07-05 2016-05-03 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
KR101110013B1 (ko) * 2007-10-05 2012-02-29 (주)바이오니아 서열 내에 어베이직 부분을 포함하는 ｐｃｒ 증폭용프라이머
ES2627745T3 (es) 2008-11-13 2017-07-31 Nogra Pharma Limited Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
HK1200484A1 (zh) * 2011-09-14 2015-08-07 Translate Bio Ma, Inc. 多聚寡核苷酸化合物
EP2895200B1 (en) * 2012-09-14 2019-11-06 Translate Bio MA, Inc. Multimeric oligonucleotide compounds
US10077443B2 (en) * 2012-11-15 2018-09-18 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
EP2959000B1 (en) * 2013-02-25 2018-08-15 Integrated DNA Technologies Inc. Naphthyl-azo modifications for antisense compounds
DK2991656T3 (da) * 2013-05-01 2020-03-23 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
WO2016024205A1 (en) * 2014-08-15 2016-02-18 Pfizer Inc. Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
PH12018501207B1 (en) * 2015-12-21 2024-02-23 Novartis Ag Compositions and methods for decreasing tau expression
BR112021000308A2 (pt) * 2018-07-25 2021-04-13 Ionis Pharmaceuticals, Inc. Compostos e métodos para redução da expressão de atxn2
US20220372489A1 (en) * 2019-06-21 2022-11-24 Quralis Corporation Ppm1a inhibitors and methods of using same

Similar Documents

Publication Publication Date Title
CN111373043B (zh) 用于降低snca表达的化合物和方法
US20250051766A1 (en) Treatment of neurological diseases using modulators of unc13a gene transcripts
TWI870557B (zh) 用於調節ｓｍｎ２之化合物及方法
CA3227115A1 (en) Unc13a antisense oligonucleotides
WO2023102242A2 (en) Splice switcher antisense oligonucleotides with modified backbone chemistries
IL313205A (en) Microbial consortia
JPWO2020247419A5 (https=)
JPWO2023102188A5 (https=)
JPWO2023102225A5 (https=)
JPWO2023102242A5 (https=)
TW202216176A (zh) 包括表現腫瘤壞死因子可誘導基因６的間葉幹細胞之組成物及藥物組成物
CN119452086A (zh) 具有修饰的主链化学的gapmer反义寡核苷酸
JPWO2020257631A5 (https=)
AU2024215901A1 (en) Syf2 antisense oligonucleotides
WO2023102548A1 (en) Treatment of neurological diseases using modulators of kcnq2 gene transcripts
JP2025514346A (ja) Ｓｙｆ２アンチセンスオリゴヌクレオチド
RU2024118442A (ru) Лечение неврологических заболеваний с применением модуляторов транскриптов гена unc13a
HK40121931A (zh) 具有修饰的主链化学的gapmer反义寡核苷酸
CA2610413A1 (en) Uses of oligonucleotides stimulatory of the mesenchymal stem cell proliferation
EP4495242A1 (en) Antisense nucleic acid capable of inhibiting biosynthesis of chondroitin sulfate
JP2008184396A (ja) 神経損傷に起因する身体機能障害の予防及び治療のための医薬
JP7034314B2 (ja) うつ病を予防または治療するための安息香酸またはその塩および誘導体
TW202540422A (zh) 用於治療與ｕｂｅ３ａ過表現相關之疾患之組合物及方法
JPWO2021247800A5 (https=)
JP2023137052A (ja) コンドロイチン硫酸生合成を阻害するアンチセンス核酸